Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Evommune Presents EVO570 Development Plan Targeting Rheumatoid Arthritis

By Public Technologies
  • Evommune plans to begin Phase 2 development of EVO570 in rheumatoid arthritis in 2027, targeting data in Q4 2028.
  • Phase 1 is expected to start around late January 2027, with healthy-volunteer data due around mid-2027.
  • Rights outside Greater China involve $20 million upfront cash, $10 million in warrants exercisable for Evommune stock, issued at signing.
  • A $10 million milestone is payable at Phase 2 initiation; royalties range from mid-single to low-double-digit percentages of net sales.
  • Preclinical comparisons showed roughly 20-fold greater VAV1 degradation potency than Novartis’ MRT-6160, with maximum degradation of 99% versus 97%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.